Cluster headache: Galcanezumab Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks. In weekly clusters compared to placebo during the weeks […]
Cluster headache: Galcanezumab Read More »
Migraine and genetic Migraine is associated with a polygenic inheritance Migraines and genetic: A new study has found that some families are especially sensitive to Migraines and that genetics influences the type of migraine suffered by affected people. Migraine is a disease that has as its main symptom headache, throbbing, unilateral, accompanied by nausea or
Migraine and genetic Read More »
CGRP as the target of new migraine therapies — successful translation from bench to clinic You can now download the document here: —–> CGRP as the target of new migraine therapies — successful translation from bench to clinic Treatment of migraine is on the cusp of a new era with the development of drugs that target
CGRP as the target of new migraine therapies Read More »
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar
New measures to avoid valproate exposure in pregnancy Read More »
The European Medicines Agency’s experts in medicines safety, the Pharmacovigilance Risk Assessment Committee (PRAC) are recommending new measures to avoid exposure of babies to valproate medicines in the womb. Babies exposed are at risk of malformations and developmental problems. The PRAC examined the available evidence and consulted widely with healthcare professionals and with patients, including women
PRAC recommends new measures to avoid valproate exposure in pregnancy Read More »
Laboratory-made antibody Erenumab blocks neural brain pathway and is first new treatment for attacks approved in 20 years A new migraine drug that can halve the length of time sufferers are laid low by the debilitating condition has been hailed as an “incredibly important” advance. Erenumab, a laboratory-made antibody that blocks a neural brain pathway
New Migraine drug hailed as “Incredibly important” breakthrough Read More »
European Federation of Neurological Associations Training initiatives for neurology advocates❕❕ EFNA´s Training initiatives in SPAIN #campusdiversia#EMHAumbrella The 26th 27th of October 2017, the European Federation of Neurological associations develop together with the support of Elena Ruiz de la Torre, president of European headache alliance, an extraordinary Training initiative for Neurological Associations in Valencia ,Spain. This
EFNA´s Training initiatives in SPAIN Read More »
Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of
Positive Phase III data for migraine drug Fremanezumab Read More »
OBJECTIVES: The aim of this study was to evaluate the efficacy of greater occipital nerve (GON) block in the treatment of migraine patients. METHODS: This study included 28 patients diagnosed with migraine between 2014 and 2015. The GON block procedure was applied by administering 1.5 ml of 2% lidocaine 2 cm lateral and 2 cm
The results of greater occipital nerve block applied for migraine headache Read More »
Patients with chronic migraine share features with individuals with temporomandibular disorders that include kinesiophobia and neck disability, according to a cross-sectional study recently published in Pain Medicine.1 A growing body of research indicates a number of shared features between chronic migraine and TMD. For example, patients with chronic migraine, but not headache-free individuals, commonly experience
Disability & Catastrophizing In Chronic Migraine vs Temporomandibular Disorder Read More »
